Here, we found that miR-26a is highly expressed in TKI-resistant NSCLC cells, and that miR-26a promotes the proliferation and confers TKI resistance of lung cancer cells by inhibiting protein tyrosine phosphatase non-receptor type 13 (PTPN13); PTPN13 downregulation increases Src activation and enhances EGFR downstream signaling. Here, SRC is linked to non-small cell lung carcinoma.